Health Score

0 Poor

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Add abstracts to 5435 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact5435 DOIs

Deposit reference lists for 5272 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact5272 DOIs

Attach ORCID iDs across 5272 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact5272 DOIs

DOIs for this ISSN

Showing the top 5 of 5435 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Insomnia, anxiety and related disorders: a systematic review… (10.1016/j.nsa.2024.103936)	Abstract ORCID	93.75	74
2	Safety and efficacy of KarXT (xanomeline–trospium) in patien… (10.1016/j.nsa.2022.100288)	Abstract References ORCID	75.00	9
3	Nose to brain delivery of flurbiprofen from a solid lipid na… (10.1016/j.nsa.2024.104062)	Abstract ORCID	58.80	14
4	Sex-based modulation of endoplasmic reticulum stress and ant… (10.1016/j.nsa.2023.101028)	Abstract References ORCID	58.36	5
5	Modafinil-induced changes in the functional thalamic connect… (10.1016/j.nsa.2023.103876)	Abstract References ORCID	58.36	5
6	The STRESS-EU database: A European resource of human acute s… (10.1016/j.nsa.2024.104063)	Abstract ORCID	55.70	12
7	Humidity as the meteorological factor that influences season… (10.1016/j.nsa.2022.100181)	Abstract References ORCID	52.42	4
8	The aftermath of COVID-19 lockdown: Self-harm and suicide-re… (10.1016/j.nsa.2022.100966)	Abstract References ORCID	52.42	4
9	Pharmacokinetics and pharmacokinetic-pharmacodynamic relatio… (10.1016/j.nsa.2022.100410)	Abstract References ORCID	45.15	3
10	Perceived immune fitness, depression, and dietary zinc intak… (10.1016/j.nsa.2022.100497)	Abstract References ORCID	45.15	3
11	Reduced levels of α-Klotho are associated with increase in o… (10.1016/j.nsa.2023.101034)	Abstract References ORCID	45.15	3
12	Hotspot SPTLC2 gain-of-function mutation links dysregulated… (10.1016/j.nsa.2023.102696)	Abstract References ORCID	45.15	3
13	Vitamin B12, homocysteine and folic acid in obsessive-compul… (10.1016/j.nsa.2023.103450)	Abstract References ORCID	45.15	3
14	Methodological challenges in psychedelic drug trials: Effica… (10.1016/j.nsa.2022.100104)	Abstract	40.05	39
15	Prospects for improved prevention and treatment of neuropsyc… (10.1016/j.nsa.2022.100103)	Abstract ORCID	38.91	5
16	Translational models of stress and resilience: An applied ne… (10.1016/j.nsa.2024.104064)	Abstract	37.63	31
17	Recommendations, guidelines, and best practice for the use o… (10.1016/j.nsa.2023.101125)	Abstract	37.28	30
18	Evaluation of the α-synuclein PET radiotracer (d3)-[11C]MODA… (10.1016/j.nsa.2022.100016)	Abstract References ORCID	35.78	2
19	Activation of NOX/NADPH oxidase and mitochondrial damage in… (10.1016/j.nsa.2022.100344)	Abstract References ORCID	35.78	2
20	Effect of HTL0045725, a selective agonist of the orphan rece… (10.1016/j.nsa.2022.100412)	Abstract References ORCID	35.78	2
21	The safety and efficacy of COMP360 psilocybin therapy in tre… (10.1016/j.nsa.2022.100511)	Abstract References ORCID	35.78	2
22	Does reserpine cause depression? A systematic review (10.1016/j.nsa.2022.100524)	Abstract References ORCID	35.78	2
23	Antipsychotic prescribing trends in schizophrenia between 20… (10.1016/j.nsa.2022.100636)	Abstract References ORCID	35.78	2
24	Effects of the novel phosphodiesterase-2 inhibitor BI 474121… (10.1016/j.nsa.2022.100699)	Abstract References ORCID	35.78	2
25	Impaired balance of oxidative DNA damage and base excision r… (10.1016/j.nsa.2022.100812)	Abstract References ORCID	35.78	2
26	Back to basics: the importance of dose in psychiatric resear… (10.1016/j.nsa.2023.101058)	Abstract References ORCID	35.78	2
27	Home and epigenome: How DNA methylation could explain the as… (10.1016/j.nsa.2023.101111)	Abstract References ORCID	35.78	2
28	Longitudinal trajectory of obsessive-compulsive symptoms in… (10.1016/j.nsa.2023.101112)	Abstract References ORCID	35.78	2
29	Evaluation of the pharmacokinetics of TV-44749, newly develo… (10.1016/j.nsa.2023.102503)	Abstract References ORCID	35.78	2
30	ADHD diagnosis based on action characteristics recorded in v… (10.1016/j.nsa.2023.102835)	Abstract References ORCID	35.78	2
31	Eveningness and diurnal rhythm disruptions are associated wi… (10.1016/j.nsa.2023.102902)	Abstract References ORCID	35.78	2
32	Prenatal antidepressant exposure and offspring brain morphol… (10.1016/j.nsa.2023.103325)	Abstract References ORCID	35.78	2
33	Influence of CYP2C19 and CYP2D6 on side-effects of aripipraz… (10.1016/j.nsa.2023.103331)	Abstract References ORCID	35.78	2
34	The SOLARIS protocol: a phase 3, randomized, double-blind, p… (10.1016/j.nsa.2023.103589)	Abstract References ORCID	35.78	2
35	GLP-1 receptor agonist semaglutide reduces appetite while in… (10.1016/j.nsa.2023.103925)	Abstract	35.78	26
36	Thought and mood/arousal disturbances as central broad dimen… (10.1016/j.nsa.2024.103951)	Abstract References ORCID	35.78	2
37	The prototypical hallucinogen LSD produces rapid antidepress… (10.1016/j.nsa.2024.103986)	Abstract References ORCID	35.78	2
38	Exploration of MDMA-assisted therapy for major depressive di… (10.1016/j.nsa.2024.104179)	Abstract References ORCID	35.78	2
39	Maintenance of Efficacy of KarXT (Xanomeline and Trospium) i… (10.1016/j.nsa.2024.104220)	Abstract References ORCID	35.78	2
40	A long-acting subcutaneous injectable formulation of olanzap… (10.1016/j.nsa.2024.104230)	Abstract References ORCID	35.78	2
41	The neurophysiological and neuropsychological assessment in… (10.1016/j.nsa.2024.104455)	Abstract References ORCID	35.78	2
42	Topline Results: a double-blind, randomized placebo-controll… (10.1016/j.nsa.2024.105120)	Abstract References ORCID	35.78	2
43	Efficacy and safety of esketamine nasal spray as monotherapy… (10.1016/j.nsa.2024.105279)	Abstract References ORCID	35.78	2
44	deepmriprep: Voxel-based Morphometry (VBM) Preprocessing via… (10.1016/j.nsa.2025.105423)	Abstract References ORCID	35.78	2
45	Absolute neutrophil count (ANC) and adverse drug reaction (A… (10.1016/j.nsa.2025.105815)	Abstract References ORCID	35.78	2
46	Safety pharmacology of acute psilocybin administration in he… (10.1016/j.nsa.2024.104060)	Abstract	35.37	25
47	Virtual Reality exposure therapy in the treatment of public… (10.1016/j.nsa.2024.104074)	Abstract	35.37	25
48	A review of psychedelics trials completed in depression, inf… (10.1016/j.nsa.2025.105516)	Abstract ORCID	34.95	4
49	A digital self-help tool to promote mental well-being for Uk… (10.1016/j.nsa.2024.104089)	Abstract	31.97	18
50	Polygenic risk scores and brain structures both contribute t… (10.1016/j.nsa.2023.101128)	Abstract	31.38	17